Literature DB >> 30594473

Recent advances on porphyria genetics: Inheritance, penetrance & molecular heterogeneity, including new modifying/causative genes.

Makiko Yasuda1, Brenden Chen2, Robert J Desnick3.   

Abstract

The inborn errors of heme biosynthesis, the Porphyrias, include eight major disorders resulting from loss-of-function (LOF) or gain-of-function (GOF) mutations in eight of the nine heme biosynthetic genes. The major sites of heme biosynthesis are the liver and erythron, and the underlying pathophysiology of each of these disorders depends on the unique biochemistry, cell biology, and genetic mechanisms in these tissues. The porphyrias are classified into three major categories: 1) the acute hepatic porphyrias (AHPs), including Acute Intermittent Porphyria (AIP), Hereditary Coproporphyria (HCP), Variegate Porphyria (VP), and 5-Aminolevlulinic Acid Dehydratase Deficient Porphyria (ADP); 2) a hepatic cutaneous porphyria, Porphyria Cutanea Tarda (PCT); and 3) the cutaneous erythropoietic porphyrias, Congenital Erythropoietic Porphyria (CEP), Erythropoietic Protoporphyria (EPP), and X-Linked Protoporphyria (XLP). Their modes of inheritance include autosomal dominant with markedly decreased penetrance (AIP, VP, and HCP), autosomal recessive (ADP, CEP, and EPP), or X-linked (XLP), as well as an acquired sporadic form (PCT). There are severe homozygous dominant forms of the three AHPs. For each porphyria, its phenotype, inheritance pattern, unique genetic principles, and molecular genetic heterogeneity are presented. To date, >1000 mutations in the heme biosynthetic genes causing their respective porphyrias have been reported, including low expression alleles and genotype/phenotype correlations that predict severity for certain porphyrias. The tissue-specific regulation of heme biosynthesis and the unique genetic mechanisms for each porphyria are highlighted.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30594473      PMCID: PMC6542720          DOI: 10.1016/j.ymgme.2018.11.012

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  83 in total

1.  Identification and characterization of hydroxymethylbilane synthase mutations causing acute intermittent porphyria: evidence for an ancestral founder of the common G111R mutation.

Authors:  A De Siervi; M V Rossetti; V E Parera; K H Astrin; G I Aizencang; I A Glass; A M Batlle; R J Desnick
Journal:  Am J Med Genet       Date:  1999-10-08

Review 2.  Congenital erythropoietic porphyria: advances in pathogenesis and treatment.

Authors:  Robert J Desnick; Kenneth H Astrin
Journal:  Br J Haematol       Date:  2002-06       Impact factor: 6.998

3.  C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload.

Authors:  Sharon D Whatley; Sarah Ducamp; Laurent Gouya; Bernard Grandchamp; Carole Beaumont; Michael N Badminton; George H Elder; S Alexander Holme; Alexander V Anstey; Michelle Parker; Anne V Corrigall; Peter N Meissner; Richard J Hift; Joanne T Marsden; Yun Ma; Giorgina Mieli-Vergani; Jean-Charles Deybach; Hervé Puy
Journal:  Am J Hum Genet       Date:  2008-09-04       Impact factor: 11.025

4.  Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria.

Authors:  H Puy; J C Deybach; J Lamoril; A M Robreau; V Da Silva; L Gouya; B Grandchamp; Y Nordmann
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

5.  Digenic inheritance of mutations in the coproporphyrinogen oxidase and protoporphyrinogen oxidase genes in a unique type of porphyria.

Authors:  Anne Moniek van Tuyll van Serooskerken; Felix W de Rooij; Annie Edixhoven; Reno S Bladergroen; Jens M Baron; Sylvia Joussen; Hans F Merk; Peter M Steijlen; Pamela Poblete-Gutiérrez; Kornelis te Velde; J H Paul Wilson; Rita H Koole; Michel van Geel; Jorge Frank
Journal:  J Invest Dermatol       Date:  2011-07-07       Impact factor: 8.551

6.  Crystal structure of human uroporphyrinogen decarboxylase.

Authors:  F G Whitby; J D Phillips; J P Kushner; C P Hill
Journal:  EMBO J       Date:  1998-05-01       Impact factor: 11.598

Review 7.  Porphyria.

Authors:  D Montgomery Bissell; Karl E Anderson; Herbert L Bonkovsky
Journal:  N Engl J Med       Date:  2017-08-31       Impact factor: 91.245

8.  Identification of the mutations in the parents of a patient with a putative compound heterozygosity for acute intermittent porphyria.

Authors:  C Picat; M H Delfau; F W de Rooij; G J Beukeveld; B G Wolthers; S K Wadman; Y Nordmann; B Grandchamp
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

9.  Acquired erythropoietic uroporphyria secondary to myelodysplastic syndrome with chromosome 3 alterations: a case report.

Authors:  S Podlipnik; F Guijarro; A Combalia; J To-Figueras; C Badenas; D Costa; M Rozman; S Jorge; P Aguilera; A Gaya
Journal:  Br J Dermatol       Date:  2018-03-02       Impact factor: 9.302

10.  Evidence for an ancestral founder of the common R116W mutation in the hydroxymethylbilane synthase gene in acute intermittent porphyria in The Netherlands.

Authors:  F W M de Rooij; F G Kavelaars; H Koole-Lesuis; J H P Wilson
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2009-07-01       Impact factor: 1.770

View more
  14 in total

Review 1.  Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs).

Authors:  Herbert L Bonkovsky; Natalia Dixon; Sean Rudnick
Journal:  Mol Genet Metab       Date:  2019-03-06       Impact factor: 4.797

2.  Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP.

Authors:  Michael Linenberger; Kleber Y Fertrin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 3.  Psychological Aspect and Quality of Life in Porphyrias: A Review.

Authors:  Granata Francesca; Annamaria Nicolli; Alessia Colaiocco; Elena Di Pierro; Giovanna Graziadei
Journal:  Diagnostics (Basel)       Date:  2022-05-10

Review 4.  Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.

Authors:  Pedro Renato de Paula Brandão; Simoneide S Titze-de-Almeida; Ricardo Titze-de-Almeida
Journal:  Mol Diagn Ther       Date:  2020-02       Impact factor: 4.074

5.  Acitretin mitigates uroporphyrin-induced bone defects in congenital erythropoietic porphyria models.

Authors:  Juliana Bragazzi Cunha; Jared S Elenbaas; Dhiman Maitra; Ning Kuo; Rodrigo Azuero-Dajud; Allison C Ferguson; Megan S Griffin; Stephen I Lentz; Jordan A Shavit; M Bishr Omary
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.379

Review 6.  Novel treatment options for acute hepatic porphyrias.

Authors:  Bruce Wang
Journal:  Curr Opin Gastroenterol       Date:  2021-05-01       Impact factor: 2.741

Review 7.  Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators.

Authors:  Helene J Bustad; Juha P Kallio; Marta Vorland; Valeria Fiorentino; Sverre Sandberg; Caroline Schmitt; Aasne K Aarsand; Aurora Martinez
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

8.  Two Novel Hydroxymethylbilane Synthase Splicing Mutations Predispose to Acute Intermittent Porphyria.

Authors:  Yanping Zhang; Han Xiao; Qiuhong Xiong; Changxin Wu; Ping Li
Journal:  Int J Mol Sci       Date:  2021-10-12       Impact factor: 5.923

Review 9.  Iron in Porphyrias: Friend or Foe?

Authors:  Elena Buzzetti; Paolo Ventura; Elena Corradini
Journal:  Diagnostics (Basel)       Date:  2022-01-21

10.  Iron Hack - A symposium/hackathon focused on porphyrias, Friedreich's ataxia, and other rare iron-related diseases.

Authors:  Gloria C Ferreira; Jenna Oberstaller; Renée Fonseca; Thomas E Keller; Swamy Rakesh Adapa; Justin Gibbons; Chengqi Wang; Xiaoming Liu; Chang Li; Minh Pham; Guy W Dayhoff Ii; Ben Busby; Rays H Y Jiang; Linh M Duong; Luis Tañón Reyes; Luciano Enrique Laratelli; Douglas Franz; Segun Fatumo; Atm Golam Bari; Audrey Freischel; Lindsey Fiedler; Omkar Dokur; Krishna Sharma; Deborah Cragun
Journal:  F1000Res       Date:  2019-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.